Taro Pharmaceuticals announced that it has received approval from the FDA for its New Drug Application (NDA) for Topicort (desoximetasone) Topical Spray.

Topicort is a corticosteroid indicated for the treatment of plaque psoriasis in patients >18 years old. Topical corticosteroids possess anti-inflammatory, antipruritic and vasoconstrictive actions to treat various skin disorders.  

Topicort Topical Spray will be available in a 0.25% strength. Other Topicort products include Topicort Ointment (desoximetasone 0.25%), Topicort Gel (desoximetasone 0.05%), and Topicort-LP Cream (desoximetasone 0.05%).

For more information call (800) 544-1449 or visit www.taro.com.